• We are available for your help 24/7
  • Email: info@isindexing.com, submission@isindexing.com

Paper Details


Revi Kumar. KG, Mohsina Hyder.K, Shahina PT, Veena R*

Journal Title:World Journal of Pharmaceutical Research

Diabetes is the fourth or fifth leading cause of death in most high income countries. The number of people with diabetes is increasing due to population growth, aging, urbanization and increasing prevalence of obesity, sedentary life and lack of physical activities. In the age group of 35- 64 years, 1 out of 10 deaths are estimated to be due to diabetes. The primary goal of type 2 DM treatment is to achieve and maintain good glycemic control, and to reduce the mortality. Metformin, dimethyl biguanide, originally marketed as Glucophage in 1957 is believed to be the most widely prescribed anti-diabetic drug in the world. Metformin improves glucose tolerance in diabetic patients, lowering both basal and post prandial plasma glucose. Metformin also has positive effects on several components of the insulin resistance syndrome. Metformin decreases plasma triglycerides and LDL-C by approximately 8% to 15%, as well increasing HDL-C very modestly (2%). Metformin reduces levels of plasminogen activator inhibitor-1 and causes a modest reduction in weight (2 to 3 kg). It is a time tested trustworthy medicine for the management of Type 2 diabetes and is having a good safety profile. Metformin became available in the British National Formulary in 1958 and was approved in Canada in 1972. In the United States alone, about 50 million prescriptions are filled in a year for its generic formulations. By 2014 metformin formulations became the largest selling pharmaceutical formulation in India with a sales turnover of 1050 million INR.